$1.32
+0.01(0.76%)
Mkt Cap $14M
$0.85
$2.19
52-Week Range
At A Glance
1
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the trea...
2
Revenue is primarily driven by Grant (37.6%) and Cprit Grant (27%).
3
Most recently: . Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGN (2026-02-09).
$14M
Market Cap
—
Revenue
—
Net Income
Employees5
Fundamentals
How The Business Makes Money
Revenue by Segment
Grant37.6%($10M)
Cprit Grant27%($7M)
Related Party Service9.5%($3M)
National Institutes Of Health Small Business Innovation Research For Pancreatic Cancer7.6%($2M)
National Institutes Of Health National Cancer Institute Grant7.6%($2M)
National Institutes Of Health Small Business Innovation Research4.6%($1M)
Fda Grant3.4%($900.0K)
National Institutes Of Health Small Business Innovation Research For Lymphoma Grant2.7%($700.0K)
Activity
Analyst View
Company Profile
CIK0001094038
ISINUS57055L2060
CUSIP57055L107
Phone713 400 6400
Address3200 Southwest Freeway, Houston, TX, 77027, US
SEC EDGAR